Anti-Human PD-1&CTLA-4 Reference Antibody|抗人PD-1和CTLA-4参考抗体(靶标：人PD-1/CTLA-4)
- 货号：RB9THS870386
- 价格：面议
- 点击：599
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 宿主种属 | Human |
| 克隆性 | Monoclonal |
| 抗体亚型 | IgG1-kappa_scFv |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 浓度 | 1mg/ml |
| 内毒素水平 | Please contact the lab for this information. |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 种属反应性 | Human |
| 靶标 | Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279, CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4 |
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 表达系统 | Mammalian Cells |
| 登录号 | Q15116 & P16410 |
| 背景信息 | Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody. • Cancer immunotherapy using checkpoint blockade., PMID:29567705 • The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870 • Immune-related adverse events of checkpoint inhibitors., PMID:32382051 • Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845 • Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113 • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885 • Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160 • Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858 • Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360 • Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704 |
| 别名 | 2599198-80-6 |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
相关产品:
